Molecular insights into P2X signalling cascades in acute kidney injury.
Acute kidney injury
Adenosine triphosphate
Ion channels
P2X receptor antagonists
P2X receptors
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
22 Jan 2024
22 Jan 2024
Historique:
received:
23
11
2023
accepted:
18
01
2024
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
21
1
2024
Statut:
aheadofprint
Résumé
Acute kidney injury (AKI) is a critical health issue with high mortality and morbidity rates in hospitalized individuals. The complex pathophysiology and underlying health conditions further complicate AKI management. Growing evidence suggests the pivotal role of ion channels in AKI progression, through promoting tubular cell death and altering immune cell functions. Among these channels, P2X purinergic receptors emerge as key players in AKI pathophysiology. P2X receptors gated by adenosine triphosphate (ATP), exhibit increased extracellular levels of ATP during AKI episodes. More importantly, certain P2X receptor subtypes upon activation exacerbate the situation by promoting the release of extracellular ATP. While therapeutic investigations have primarily focused on P2X
Identifiants
pubmed: 38246970
doi: 10.1007/s11302-024-09987-w
pii: 10.1007/s11302-024-09987-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Mehta RL et al (2015) International society of nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. The Lancet 385(9987):2616–2643
Wilhelm K et al (2010) Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 16(12):1434–1438
pubmed: 21102458
Sluyter R et al (2023) Purinergic signalling in graft-versus-host disease. Curr Opin Pharmacol 68:102346
pubmed: 36634595
Bailey MA, Unwin RJ, Shirley DG (2012) P2X receptors and kidney function. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling 1(4):503–511
Zhang W et al (2022) The role of the superior cervical sympathetic ganglion in ischemia reperfusion-induced acute kidney injury in rats. Front Med 9:792000
Han SJ et al (2020) P2X4 receptor exacerbates ischemic AKI and induces renal proximal tubular NLRP3 inflammasome signaling. FASEB J 34(4):5465–5482
pubmed: 32086866
Qian Y et al (2021) P2X7 receptor signaling promotes inflammation in renal parenchymal cells suffering from ischemia-reperfusion injury. Cell Death Dis 12(1):132
pubmed: 33504771
pmcid: 7841183
Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signalling 14(1):1–18
pubmed: 29164451
Pichler R et al (2017) Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol 312(4):F716–F731
pubmed: 27558558
Mahmood A, Iqbal J (2022) Purinergic receptors modulators: an emerging pharmacological tool for disease management. Med Res Rev 42(4):1661–1703
pubmed: 35561109
Illes P et al (2021) Update of P2X receptor properties and their pharmacology: IUPHAR review 30. Br J Pharmacol 178(3):489–514
pubmed: 33125712
Osmond DA, Inscho EW (2010) P2X(1) receptor blockade inhibits whole kidney autoregulation of renal blood flow in vivo. Am J Physiol Renal Physiol 298(6):F1360–F1368
pubmed: 20335318
pmcid: 2886815
Franco M et al (2017) Physiopathological implications of P2X1 and P2X7 receptors in regulation of glomerular hemodynamics in angiotensin II-induced hypertension. Am J Physiology-Renal Physiol 313(1):F9–F19
Rettinger J, Schmalzing G (2004) Desensitization masks nanomolar potency of ATP for the P2X1 receptor. J Biol Chem 279(8):6426–6433
pubmed: 14625300
Ennion SJ, Evans RJ (2001) Agonist-stimulated internalisation of the ligand‐gated ion channel P2X1 in rat vas deferens. FEBS Lett 489(2–3):154–158
pubmed: 11165241
Bennetts FM et al (2022) The P2X1 receptor as a therapeutic target. Purinergic Signalling 18(4):421–433
pubmed: 35821454
pmcid: 9832217
Vial C, Evans RJ (2002) P2X1 receptor-deficient mice establish the native P2X receptor and a P2Y6-like receptor in arteries. Mol Pharmacol 62(6):1438–1445
pubmed: 12435812
Billaud M et al (2011) Pannexin1 regulates α1-adrenergic receptor– mediated vasoconstriction. Circul Res 109(1):80–85
Kluess HA et al (2005) Acidosis attenuates P2X purinergic vasoconstriction in skeletal muscle arteries. Am J Physiol Heart Circ Physiol 288(1):H129–H132
pubmed: 15374827
Mancinelli R et al (2014) Extracellular GTP is a potent water-transport regulator via aquaporin 5 plasma-membrane insertion in M1-CCD epithelial cortical collecting duct cells. Cell Physiol Biochem 33(3):731–746
pubmed: 24662389
Kuczeriszka M et al (2016) Influence of P2X receptors on renal medullary circulation is not altered by angiotensin II pretreatment. Pharmacol Rep 68:1230–1236
pubmed: 27682519
Wildman SS et al (2009) Nucleotides downregulate aquaporin 2 via activation of apical P2 receptors. J Am Soc Nephrol 20(7):1480–1490
pubmed: 19423692
pmcid: 2709676
Craigie E et al (2018) The renal and blood pressure response to low sodium diet in P2X4 receptor knockout mice. Physiological Rep 6(20):e13899
Burnstock G, M.A. Evans Lc Fau - Bailey, and Bailey MA (1573–9546 (Electronic)) Purinergic signalling in the kidney in health and disease.
Kim H et al (2017) The purinergic receptor P2X5 regulates inflammasome activity and hyper-multinucleation of murine osteoclasts. Sci Rep 7(1):196
pubmed: 28298636
pmcid: 5427844
Kim H et al (2018) The purinergic receptor P2X5 contributes to bone loss in experimental periodontitis. BMB Rep 51(9):468–473
pubmed: 30103845
pmcid: 6177510
Turner CM et al (2003) The pattern of distribution of selected ATP-sensitive P2 receptor subtypes in normal rat kidney: an immunohistological study. Cells Tissues Organs 175(2):105–117
pubmed: 14605489
Vallon V et al (2020) Extracellular nucleotides and P2 receptors in renal function. Physiol Rev 100(1):211–269
pubmed: 31437091
de Baaij JHF et al (2016) P2X6 knockout mice exhibit normal electrolyte homeostasis. PLoS ONE 11(6):e0156803
pubmed: 27254077
pmcid: 4890750
Hillman KA, Burnstock G, Unwin RJ (2005) The P2X7 ATP receptor in the kidney: a matter of life or death? Nephron Experimental Nephrology 101(1):e24–e30
pubmed: 15925905
Jiang L-H et al (2021) Structural basis for the functional properties of the P2X7 receptor for extracellular ATP. Purinergic Signalling 17(3):331–344
pubmed: 33987781
pmcid: 8410900
Di Virgilio F, Schmalzing G, Markwardt F (2018) The elusive P2X7 macropore. Trends Cell Biol 28(5):392–404
pubmed: 29439897
Serife C-S, Kemal S, Mehmet U (2009) P2X7 receptor activates multiple selective dye-permeation pathways in RAW 264.7 and human embryonic kidney 293 cells. Mol Pharmacol 76(6):1323
Gonçalves RG et al (2006) The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 70(9):1599–1606
pubmed: 16969386
Menzies RI et al (2013) Effect of P2X4 and P2X7 receptor antagonism on the pressure diuresis relationship in rats. Front Physiol 4:305
pubmed: 24187541
pmcid: 3807716
Feng W et al (2021) Restoration of afferent arteriolar autoregulatory behavior in ischemia-reperfusion injury in rat kidneys. Am J Physiology-Renal Physiol 320(3):F429–F441
Guan Z et al (2023) Mitochondria and renal microvascular dysfunction following ischemia-reperfusion in rats. Physiology 38(S1):5729680
Inscho EW et al (2003) Physiological role for P2X 1 receptors in renal microvascular autoregulatory behavior. J Clin Investig 112(12):1895–1905
pubmed: 14679185
pmcid: 296993
Inscho EW et al (2004) Renal autoregulation in P2X1 knockout mice. Acta Physiol Scand 181(4):445–453
pubmed: 15283757
Menzies RI et al (2017) Purinergic signaling in kidney disease. Kidney Int 91(2):315–323
pubmed: 27780585
Davenport AJ et al (2021) Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers. Sci Rep 11(1):19877
pubmed: 34615939
pmcid: 8494816
Gao L et al (2023) The ethanol extract of scutellaria baicalensis georgi attenuates complete Freund’s adjuvant (CFA)-induced inflammatory pain by suppression of P2X3 receptor. J Ethnopharmacol 116762.
Cao W et al (2016) Reno-cerebral reflex activates the renin-angiotensin system, promoting oxidative stress and renal damage after ischemia-reperfusion injury. Antioxid Redox Signal 27(7):415–432
Grisk O (2020) The sympathetic nervous system in acute kidney injury. Acta Physiol 228(2):e13404
Cui W-W et al (2022) P2X3-selective mechanism of gefapixant, a drug candidate for the treatment of refractory chronic cough. Comput Struct Biotechnol J 20:1642–1653
pubmed: 35465163
pmcid: 9014320
Richards D et al (2019) Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. Br J Pharmacol 176(13):2279–2291
pubmed: 30927255
pmcid: 6555852
Birring SS et al (2021) P60 patient-reported improvements with gefapixant, a P2X3-receptor antagonist, over 52 weeks in two phase 3 clinical trials for refractory or unexplained chronic cough. BMJ Publishing Group Ltd.
Wei Y-z et al (2023) Gefapixant, a novel P2X3 antagonist, protects against post myocardial infarction cardiac dysfunction and remodeling via suppressing NLRP3 inflammasome. Curr Med Sci 43(1):58–68
pubmed: 36622629
Thomas D, Gibson PG (2022) Gefapixant for chronic cough. The Lancet 399(10328):886–887
Nussbaum JC et al (2022) Effects of renal impairment on the pharmacokinetics of gefapixant, a P2X3 receptor antagonist. J Clin Pharmacol 62(11):1435–1444
pubmed: 35656754
Martinez FJ et al (2021) Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial. Pulmonary Therapy 7(2):471–486
pubmed: 34152585
pmcid: 8589896
Abu-Zaid A et al (2021) Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: a systematic review and meta-analysis of randomized controlled trials. Annals of Thoracic Medicine 16(2):127
pubmed: 34012479
pmcid: 8109686
Morice A et al (2021) Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J 58(5)
Klein S et al (2022) First-in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: tolerability, safety and pharmacokinetics. Br J Clin Pharmacol 88(10):4552–4564
pubmed: 35437837
Friedrich C et al (2023) The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial. Respir Res 24(1):109
pubmed: 37041539
pmcid: 10088222
Chauret N et al (2023) Model-based dose selection for phase 3 trials of the selective P2X3 antagonist camlipixant in refractory chronic cough, in B69. Airway Injury and Repair: Mechanisms and Treatment. American Thoracic Society. A4058-A4058
McGarvey L et al (2023) Response in patient-reported cough severity in soothe, a phase 2b trial of camlipixant in refractory chronic cough, in A99. Clinical Trials in Chronic Lung Disease. American Thoracic Society. A2533-A2533
Kim MJ et al (2014) Exaggerated renal fibrosis in P2X4 receptor-deficient mice following unilateral ureteric obstruction. Nephrol Dialysis Transplantation 29(7):1350–1361
Chen K et al (2013) ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy. Int J Biochem Cell Biol 45(5):932–943
pubmed: 23434541
Coddou C et al (2019) Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor. Neurosci Lett 690:219–224
pubmed: 30366010
D’Antongiovanni V et al (2022) Anti-inflammatory effects of novel P2X4 receptor antagonists, NC-2600 and NP-1815-PX, in a murine model of colitis. Inflammation 45(4):1829–1847
pubmed: 35338432
Teixeira JM et al (2019) Diabetes-induced neuropathic mechanical hyperalgesia depends on P2X4 receptor activation in dorsal root ganglia. Neuroscience 398:158–170
pubmed: 30537520
Koo TY et al (2017) The P2X7 receptor antagonist, oxidized adenosine triphosphate, ameliorates renal ischemia-reperfusion injury by expansion of regulatory T cells. Kidney Int 92(2):415–431
pubmed: 28396117
Rabadi M et al (2018) ATP induces PAD4 in renal proximal tubule cells via P2X7 receptor activation to exacerbate ischemic AKI. Am J Physiology-Renal Physiol 314(2):F293–F305
Arulkumaran N et al (2018) P2X7 receptor antagonism ameliorates renal dysfunction in a rat model of sepsis. Physiological Rep 6(5):e13622
El-Maadawy WH et al (2022) Probenecid induces the recovery of renal ischemia/reperfusion injury via the blockade of pannexin 1/P2X7 receptor axis. Life Sciences 308:120933
Thakur A et al (2023) Effect of probenecid on blood levels and renal elimination of furosemide and endogenous compounds in rats: discovery of putative organic anion transporter biomarkers. Biochem Pharmacol 218:115867
pubmed: 37866801
Doǧan E et al (2020) The role of NMDA receptors in the effect of purinergic P2X7 receptor on spontaneous seizure activity in WAG/Rij rats with genetic absence epilepsy. Front Neurosci-Switz 14
Marotta G et al (2020) Memantine derivatives as multitarget agents in Alzheimer’s disease. Molecules 25. https://doi.org/10.3390/molecules25174005
Jeong YH et al (2020) Mice lacking the purinergic receptor P2X5 exhibit defective inflammasome activation and early susceptibility to listeria monocytogenes. J Immunol 205(3):760–766
pubmed: 32540996
Kim H et al (2020) Methylosome protein 50 associates with the purinergic receptor P2X5 and is involved in osteoclast maturation. FEBS Lett 594(1):144–152
pubmed: 31432503
Dietrich F et al (2022) High P2X6 receptor expression in human bladder cancer predicts good survival prognosis. Mol Cell Biochem 477(8):2047–2057
pubmed: 35429327
Alvarez CL, Troncoso MF, Espelt MV (2022) Extracellular ATP and adenosine in tumor microenvironment: roles in epithelial–mesenchymal transition, cell migration, and invasion. J Cell Physiol 237(1):389–400
pubmed: 34514618
Collier JB, Schnellmann RG (2018) ERK1/2 regulates NAD + metabolism during acute kidney injury through microRNA-34a‐mediated NAMPT expression. FASEB J 32:562–565